Seres Therapeutics reports FY2022 net loss $250.2M, SER-109 PDUFA date April 26, 2023

Seres Therapeutics, Inc.

FY2022 net loss $250.2M vs $65.6M in FY2021; Q4 net loss $68.8M vs $50.0M.
Cash & equivalents $181.3M at Dec 31, 2022, down from $291.2M at end of 2021.
SER-109 BLA under FDA priority review with PDUFA target action date April 26, 2023; commercial launch anticipated soon after.
SER-155 Phase 1b: cohort 2 enrollment ongoing; initial safety/pharmacology data from cohort 1 expected May 2023.
Pending FDA approval, Seres expects $125M milestone payment from Nestlé Health Science.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Seres Therapeutics, Inc. reported financial results for quarter and year ended December 31, 2022.

Period: quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 7, 2023, Seres Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2022 and provided operational updates.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Seres Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-062068

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.